Bioinformatics Analysis of Hub Genes of Diabetic Foot Ulcer and Their Biofunctions

XU Fan, RUI Shun-li, LUO Pei-qi, CHEN Yan, MA Yu, DENG Wu-quan

Abstract

To explore the hub genes associated with the pathogenesis and healing of diabetic foot ulcer (DFU) and their biological functions through bioinformatics analysis of transcriptome sequencing data.   Methods  The transcriptome sequencing datasets of DFU were selected from Gene Expression Omnibus (GEO) database, and the data were regrouped and normalized for bioinformatics analysis. The skin transcriptome sequencing datasets of DFU patients were compared with those of normal controls and the transcriptome sequencing datasets of skin from ulcerous wound edge of DFU patients were compared with those of non-ulcerous skin of DFU patients so that differentially expressed genes were identified, pathway enrichment and protein-to-protein interaction (PPI) analyses were performed, hub genes were found through nodal analysis, and receiver operating characteristic (ROC) curve was applied to a testing dataset to validate the diagnostic efficiency of the hub genes related to DFU. The intersecting genes from the two sets of analyses were again subjected to pathway enrichment and PPI analyses to screen for hub genes associated with DFU wound healing. What’s more, gene set enrichment analysis (GSEA) was carried out on relevant samples to probe for the possible functions and pathway of non-significant genes in DFU.   Results  A total of 620 up-regulated differentially expressed genes and 196 down-regulated differentially expressed genes were identified in the training dataset which compared DFU patients with non-diabetic patients. The functions of these genes were enriched in the metabolism of terpenoids and polyketides, signaling molecules and interaction, phospholipase D signaling pathway, propanoate metabolism, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, pyrimidine metabolism, IL-17 signaling pathway, Rap1 signaling pathway, etc. A total of 10 hub genes were identified with the PPI network. Among them, BGN’s value of the area under the curve of ROC analysis was 0.714 and CCND1’s was 0.712. In the sequencing analysis of ulcerous wound edge of DFU patients and non-ulcerous skin of DFU patients, 4072 up-regulated genes and 911 down-regulated genes were identified, of which, 372 genes were also detected in the differentially expressed genes of DFU. The functions of these differentially expressed genes were enriched in phospholipase D signaling pathway, xenobiotics biodegradation and energy metabolism, glutathione metabolism, pyrimidine metabolism, ErbB signaling pathway, melanin production, etc. A total of 7 hub genes were identified from PPI network. In GSEA analysis, pathways including pentose and glucuronate interconversions and homologous recombination, nicotinate and nicotinamide metabolism, neuroactive ligand receptor interaction, maturity-onset diabetes of the young, butanoate metabolism, lysine degradation, pantothenate and coenzyme A biosynthesis, riboflavin metabolism, steroid hormone biosynthesis, and valine, leucine and isoleucine degradation showed significant expression differences between DFU patients and normal controls.   Conclusion  Bioinformatics analysis results suggest that BGN and CCND1 are potential biomarkers for predicting DFU; CXCL12, TLR4, JAK2, PPARA, UBC, DCN, KDR, and ARNTL are the hub genes of DFU, while CXCL8, CXCL12, TXN, SLIT3, KRT14, KIT, and NEO1 are the hub genes related to wound healing of DFU.

 

Keywords: Diabetic foot ulcer, Hub genes, Biological function, Bioinformatics

 

Full Text:

PDF


References


ZHAO J， DENG W， ZHANG Y， et al. Association between serum cystatin C and diabetic foot ulceration in patients with type 2 diabetes: A cross-sectional study. J Diabetes Res， 2016， 2016: 8029340[2022-07-27]. https://doi.org/10.1155/2016/8029340.

VIECELI DALLA SEGA F， CIMAGLIA P， MANFRINI M， et al. Circulating biomarkers of endothelial dysfunction and inflammation in predicting clinical outcomes in diabetic patients with critical limb ischemia. Int J Mol Sci，2022，23(18): 10641.

SHEN W， SONG Z， ZHONG X， et al. Sangerbox: A comprehensive， interaction-friendly clinical bioinformatics analysis platform. iMeta， 2022， 1: e36[2022-07-27]. https://doi.org/10.1002/imt2.36.

CATRINA S B， ZHENG X. Hypoxia and hypoxia-inducible factors in diabetes and its complications. Diabetologia，2021，64(4): 709–716.

DENG L， DU C， SONG P， et al. The role of oxidative stress and antioxidants in diabetic wound healing. Oxid Med Cell Longev， 2021， 2021: 8852759[2022-07-27]. https://doi.org/10.1155/2021/8852759.

XIE P， DENG B， ZHANG X， et al. Time in range in relation to amputation and all-cause mortality in hospitalised patients with diabetic foot ulcers. Diabetes Metab Res Rev， 2022， 38(2): e3498[2022-07-27]. https://doi.org/10.1002/dmrr.3498.

NOWAK N C， MENICHELLA D M， MILLER R， et al. Cutaneous innervation in impaired diabetic wound healing. Transl Res，2021，236: 87–108.

SIMONEAU A， FOUSSARD N， BLANCO L， et al. Mortality in patients with diabetic foot ulcer: Diabetic neuropathy is not innocent. A commentary on: "Amadou C et al. Five-year mortality in patients with diabetic foot ulcer during 2009–2010 was lower than expected. Diabetes Metab. 2019. DOI: 10.1016/j.diabet.2019.04.010. Diabetes Metab， 2021， 47(1): 101121[2022-07-27]. https://doi.org/10.1016/j.diabet.2019. 101121.

DENG W， DONG X， ZHANG Y， et al. Transcutaneous oxygen pressure (TcPO2): A novel diagnostic tool for peripheral neuropathy in type 2 diabetes patients. Diabetes Res Clin Pract，2014，105(3): 336–343.

DHAMODHARAN U， KARAN A， SIREESH D， et al. Tissue-specific role of Nrf2 in the treatment of diabetic foot ulcers during hyperbaric oxygen therapy. Free Radic Biol Med，2019，138: 53–62.

Li Y， Li Y， CHEN N， et al. Icariside Ⅱ exerts anti-type 2 diabetic effect by targeting PPARα/γ: Involvement of ROS/NF-κB/IRS1 signaling pathway. Antioxidants (Basel)，2022，11(9): 1705.

ROEDIG H， NASTASE M V， WYGRECKA M， et al. Breaking down chronic inflammatory diseases: The role of biglycan in promoting a switch between inflammation and autophagy. FEBS J，2019，286(15): 2965–2979.

ZHANG C， TAM T W， CHAU M K， et al. Effect of combined mycophenolate and rapamycin treatment on kidney fibrosis in murine lupus nephritis. Front Pharmacol， 2022， 13: 866077[2022-09-30]. https://doi.org/10.3389/fphar.2022.866077.

WILSON P G， THOMPSON J C， YODER M H， et al. Prevention of renal ApoB retention is protective against diabetic nephropathy: Role of TGF-β inhibition. J Lipid Res，2017，58(12): 2264–2274.

NASTASE M V， ZENG-BROUWERS J， BECKMANN J， et al. Biglycan, a novel trigger of Th1 and Th17 cell recruitment into the kidney. Matrix Biol，2018，68-69: 293–317.

BARTH M， SELIG J I， KLOSE S， et al. Degenerative aortic valve disease and diabetes: Implications for a link between proteoglycans and diabetic disorders in the aortic valve. Diab Vasc Dis Res，2019，16(3): 254–269.

LUO C， LIANG J， SHARABI K， et al. Obesity/type 2 diabetes-associated liver tumors are sensitive to Cyclin D1 deficiency. Cancer Res，2020， 80(16): 3215–3221.

TRIPATHI M， SINGH B K， LIEHN E A， et al. Caffeine prevents restenosis and inhibits vascular smooth muscle cell proliferation through the induction of autophagy. Autophagy，2022，18(9): 2150–2160.

BONORA B M， CAPPELLARI R， MAZZUCATO M， et al. Stem cell mobilization with plerixafor and healing of diabetic ischemic wounds: A phase IIa, randomized, double-blind, placebo-controlled trial. Stem Cells Transl Med，2020，9(9): 965–973.

KAUSAR M A， ANWAR S， ELTAYB W A， et al. MD simulation studies for selective phytochemicals as potential inhibitors against major biological targets of diabetic nephropathy. Molecules，2022，27(15): 4980.

SANTRA M， LIU Y C， JHANJI V， et al. Human SMILE-derived stromal lenticule scaffold for regenerative therapy: Review and perspectives. Int J Mol Sci，2022，23(14): 7967.


Refbacks

  • There are currently no refbacks.